IEFM
CRSP icon

IQ EQ Fund Management’s CRISPR Therapeutics CRSP Stock Holding History

IQ EQ Fund Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8M Sell
381,991
-18,886
-5% -$995K 1.33% 12
2026
Q1 		$19.1M Buy
400,877
+11,358
+3% +$599K 1.45% 13
2025
Q4 		$20.4M Buy
389,519
+106,408
+38% +$6.37M 1.41% 14
2025
Q3 		$18.3M Buy
283,111
+87,509
+45% +$5.02M 1.24% 16
2025
Q2 		$9.51M Buy
195,602
+130,407
+200% +$5.05M 0.85% 26
2025
Q1 		$2.22M Buy
65,195
+28,931
+80% +$1.23M 0.26% 108
2024
Q4 		$1.43M Buy
36,264
+22,647
+166% +$1.07M 0.17% 140
2024
Q3 		$640K Buy
13,617
+4,909
+56% +$249K 0.07% 247
2024
Q2 		$470K Buy
+8,708
New +$504K 0.05% 255

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IQ EQ Fund Management's CRSP Position: Q2 2026 in Review

IQ EQ Fund Management reduced its CRISPR Therapeutics (CRSP) stake by 4.7% in Q2 2026, selling an estimated $995K and leaving 381,991 shares worth $20.8M. The position accounts for 1.33% of the portfolio, ranked #12.

IQ EQ Fund Management first reported a position in CRSP in Q2 2024 and has held it in 9 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • IQ EQ Fund Management held 381,991 shares of CRISPR Therapeutics worth $20.8M as of Q2 2026.
  • IQ EQ Fund Management sold 18,886 CRISPR Therapeutics shares in Q2 2026, an estimated $995K.
  • CRISPR Therapeutics made up 1.33% of IQ EQ Fund Management's portfolio in Q2 2026, its #12 holding.
  • IQ EQ Fund Management first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on IQ EQ Fund Management's 13F filing for Q2 2026, filed 31 Jul 2026.